Andreessen Horowitz (a16z) is doubling down on healthcare AI, leading a $110 million funding round for Pearl Health, a startup using artificial intelligence to help Medicare providers shift from treating illness to preventing it. The round, announced on July 8, 2026, includes a $50 million equity investment led by a16z alongside participation from Viking Global Investors, AlleyCorp, and Ulysses Capital, plus a $60 million credit facility from Trinity Capital.

Pearl Health's funding reflects a broader shift in venture capital priorities. While much of the AI investment spotlight has focused on large language models and consumer applications, a16z and other major investors are increasingly backing AI startups tackling specific, high-stakes problems in regulated industries like healthcare. Pearl's case is particularly compelling: the company reached profitability in 2025 while managing medical spend for over 250,000 Medicare beneficiaries across 10,000 providers in 40 states.

Why Is Healthcare AI Attracting Venture Capital Right Now?

The timing of Pearl's funding reflects structural changes in how healthcare is reimbursed. Medicare and other payers are increasingly tying payments to patient outcomes rather than the volume of services provided. This shift creates powerful incentives for healthcare providers to prevent avoidable illness and intervene earlier, but most lack the technology infrastructure to do so effectively. Pearl's AI platform addresses this gap by helping providers manage risk, predict which patients are most likely to develop costly complications, and automate administrative workflows like scheduling wellness visits and post-discharge follow-ups.

The healthcare market itself is enormous. More than 70 million people rely on Medicare, with costs exceeding $1 trillion annually and climbing. This scale, combined with the regulatory environment and the clear financial incentives for AI-driven efficiency, makes healthcare an attractive sector for venture investors seeking both impact and returns.

How Does Pearl's AI Platform Create Value?

• Risk Prediction: Pearl's AI identifies at-risk patients before they develop expensive health emergencies, allowing providers to intervene with preventative care.
• Workflow Automation: The platform automates administrative tasks such as annual wellness visit scheduling, post-discharge follow-ups, and care management outreach, freeing clinicians to spend more time on direct patient care.
• Performance Intelligence: Pearl provides real-time insights on total cost of care, quality metrics, and utilization patterns, helping population health leaders surface the highest-impact actions for their unique patient populations.

Pearl's growth metrics underscore the platform's traction. The company manages approximately $3.6 billion in annualized medical spend, up from $2.4 billion the prior year and $1.6 billion two years prior. The company is projected to deliver $500 million in gross healthcare system savings and triple its patient base from 2024 through the end of 2026.

What Does a16z's Investment Signal About Venture Capital Priorities?

a16z's leadership of Pearl's round comes as the firm maintains its position as one of the most active venture investors in the United States. According to Crunchbase data, a16z led or co-led 17 venture rounds in the second quarter of 2026, ranking first among lead investors. More than two-thirds of a16z's deals in that period focused on AI-related startups.

However, a16z's Pearl investment reflects a more targeted approach than the headline-grabbing mega-rounds in large language models. Rather than betting on foundational AI models, a16z is backing companies that apply AI to solve specific, measurable problems in industries with clear economic incentives for adoption. Healthcare, with its trillion-dollar budget and regulatory pressure to improve outcomes, fits this profile perfectly.

"Pearl has demonstrated that managing risk across large patient populations across many different settings of care can improve patient outcomes, generate meaningful savings, and support a sustainable business model at scale," said Vineeta Agarwala, MD, general partner at Andreessen Horowitz. "Pearl's ability to enable providers to participate in value-based payment programs successfully, and to do so through technology rather than clinical workforce expansion, is a testament to both the vision and execution of the Pearl team."

Vineeta Agarwala, MD, General Partner at Andreessen Horowitz

Pearl's profitability milestone is particularly noteworthy. Few healthcare AI startups have achieved profitability while maintaining aggressive growth, making Pearl an outlier in a sector often characterized by long burn rates and delayed returns. This financial discipline may have been a key factor in a16z's decision to lead the round.

The broader venture capital landscape in 2026 shows that while AI investment remains robust, the focus is shifting from pure technology plays to applications with clear business models and regulatory tailwinds. Pearl Health's $110 million round demonstrates that a16z and other top-tier investors are willing to write large checks for AI startups that can prove they solve real problems at scale, even if they operate in less glamorous sectors than consumer social networks or autonomous vehicles.